Gilead's product sales excluding its COVID-19 drug rose 16% to $8.2 billion.
Gilead reported Q3 2026 product sales excluding Veklury rose 16% to $8.2B. Total sales increased 13% to $8.3B, driven by HIV products, Trodelvy, and Livdelzi. EPS decreased to $2.43, while non-GAAP EPS increased to $2.47. The company raised full-year revenue guidance.
How this was made
The 30-second read
Why it matters
The guidance suggests a deeper loss than analysts expected, likely prompting a sell‑off, though strong HIV sales and new FDA approvals may mitigate the downside.
Market read
Large‑cap biotech news with direct impact on GILD and potential spill‑over to the health‑care sector.
What to watch
The FDA approval of Bixlenvo and expanded licensing agreements could provide longer‑term upside not reflected in the short‑term guidance.
Background
Gilead announced Q3 product sales growth, higher HIV drug revenue, and updated full‑year 2026 guidance, including a GAAP loss per share of $4.40.
Ticker impact
Gilead released Q3 2026 product sales and full‑year 2026 guidance, showing a 16% sales rise and a GAAP loss per share of $4.40.
downward pressure as investors price in the widened loss guidance
The new loss guidance is material for a large‑cap biotech and is the first public disclosure of these numbers.
Market effects
Biotech and HIV therapeutic sector may see broader risk reassessment.
U.S. markets could see a modest pullback in health‑care indices.
Limited to investors with exposure to Gilead and related biotech stocks.
Counterpoint
If the market overreacts to the loss guidance, a bounce could occur on the strength of rising HIV product sales.
Key entities
- companyGilead Sciences Inc.
US‑listed biopharma reporting Q3 results and full‑year guidance.
